Loading clinical trials...

UNKNOWN

MRI-guided Lateral Lymph Node Dissection in Rectal Cancer

MAgnetic Resonance Imaging Guided LAteral Lymph Node Dissection in Lower REctal Cancer - A Multicenter, Prospective, Registry Study (MALAREC)

NCT04850027•Cancer Institute and Hospital, Chinese Academy of Medical Sciences

View on ClinicalTrials.gov

Summary

To investigate the oncological outcome of lateral lymph node dissection in low rectal cancer based on MRI

Detailed Description

Our study design is a multicenter, prospective, registry study. We would enroll 268 patients with lower rectal cancer whose preoperative MRI showed laterally lymph node diameter ≥ 5mm. The postoperative adjuvant chemoradiotherapy is determined by the pathological results. For patients of stage II and patients of stage III with unfavorable histologic features, six months of adjuvant chemotherapy of fluorouracil-based regimen with radiotherapy of 45.0 \~ 50.5 Gy are recommended. The postoperative examination should be performed every three months in the first two years and every six months in the following three years. Our study is expected to last five years, of which two years for recruiting patients, three years for follow-up.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age between 18-75 years old
•2. Pathologically confirmed as rectal adenocarcinoma
•3. The tumor is located in the middle or lower rectum
•4. Preoperative MRI assessment is T2-4 N+M0
•5. Lateral lymph node short diameter ≥ 5 mm (MRI)
•6. Signed informed consent

Exclusion Criteria

•1. Previous history of malignant colorectal tumors
•2. Multiple abdominal or pelvic surgeries were performed
•3. Complicated with bowel obstruction, perforation or bleeding
•4. Patients undergoing palliative surgery
•5. Patients with severe liver and kidney dysfunction, cardiopulmonary dysfunction, blood coagulation dysfunction, or combined with serious underlying diseases that cannot tolerate surgery
•6. Have a history of severe mental illness
•7. Pregnant or breastfeeding women （8) Patients previously treated with iliac artery surgery (or its branches)
•(9) R0 resection cannot complete (10) ASA grade ≥ IV

Locations (1)

Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College

Beijing, Beijing Municipality, China

Key Dates

Start Date

January 1, 2021

Primary Completion Date

December 31, 2022

Completion Date

December 31, 2025

Last Updated

April 26, 2021

Enrollment

268

ESTIMATED participants

Conditions

Rectal Cancer

Interventions

TME+Lateral lymph node dissection.

PROCEDURE

Contacts

Qian Liu, M.D

CONTACT

01087787110 fcwpumch@163.com

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITINGPHASE2

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 26, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

MRI-guided Lateral Lymph Node Dissection in Rectal Cancer

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Resilience and Equity in Aging, Cancer, and Health (REACH)